Cargando…
Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease?
Neuroinflammation has received increased attention as a target for putative neuroprotective therapies in Parkinson’s Disease (PD). Two prototypic pro-inflammatory cytokines interleukin-1β (IL-1) and tumor necrosis factor-α (TNF) have been implicated as main effectors of the functional consequences o...
Autores principales: | Leal, María C., Casabona, Juan C., Puntel, Mariana, Pitossi, Fernando J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638129/ https://www.ncbi.nlm.nih.gov/pubmed/23641196 http://dx.doi.org/10.3389/fncel.2013.00053 |
Ejemplares similares
-
Altered Serum Tumor Necrosis Factor and Interleukin-1β in First-Episode Drug-Naive and Chronic Schizophrenia
por: Zhu, Furong, et al.
Publicado: (2018) -
Changes in Interleukin-1β, Tumor Necrosis Factor-α, and Interleukin-10 Cytokines in Older People with Periodontitis
por: Sumbayak, Ines Augustina, et al.
Publicado: (2023) -
Tumor Necrosis Factor α and Interleukin 1β Enhance the Cortisone/Cortisol Shuttle
por: Escher, Geneviève, et al.
Publicado: (1997) -
The Degenerating Substantia Nigra as a Susceptible Region for Gene Transfer-Mediated Inflammation
por: Roca, Valeria, et al.
Publicado: (2011) -
Pretreatment serum interleukin‐1β, interleukin‐6, and tumor necrosis factor‐α levels predict the progression of colorectal cancer
por: Chang, Pei‐Hung, et al.
Publicado: (2016)